Goldman Sachs Maintains Buy on Versigent, Lowers Price Target to $58
Goldman Sachs analyst Mark Delaney maintains Versigent (NYSE:VGNT) with a Buy and lowers the price target from $59 to $58.
Stocks · News reference
8-K filing — Versigent PLC (VGNT)
Filed: 2026-08-04 AccNo: 0002078008-26-000014 Size: 468 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Versigent Q2 2026 Earnings Call Transcript
Versigent (NYSE:VGNT) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and
David Einhorn Has 7 New Stock Picks: Hedge Fund Manager Bets on Buyouts, Spinoffs
A hedge fund is betting on spinoffs and buyouts for several of its new portfolio holdings.
Argus Research Maintains Buy on Versigent, Raises Price Target to $54
Argus Research analyst Bill Selesky maintains Versigent (NYSE:VGNT) with a Buy and raises the price target from $50 to $54.